MX2007002679A - Compuestos quimicos. - Google Patents

Compuestos quimicos.

Info

Publication number
MX2007002679A
MX2007002679A MX2007002679A MX2007002679A MX2007002679A MX 2007002679 A MX2007002679 A MX 2007002679A MX 2007002679 A MX2007002679 A MX 2007002679A MX 2007002679 A MX2007002679 A MX 2007002679A MX 2007002679 A MX2007002679 A MX 2007002679A
Authority
MX
Mexico
Prior art keywords
chemical compounds
chemokine
receptor
ccr5
cxcr4
Prior art date
Application number
MX2007002679A
Other languages
English (en)
Inventor
Sharon Davis Boggs
Kristjan Gudmundsson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX2007002679A publication Critical patent/MX2007002679A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

La presente invencion proporciona compuestos novedosos que demuestran efectos protectores en celulas objetivo de infeccion por VIH en una forma tal que se unen especificamente al receptor de quimioquina, y que afectan la union del ligando natural o quimioquina a un reactor tal como CXCR4 y/o CCR5 de una celula objetivo.
MX2007002679A 2004-09-02 2005-08-28 Compuestos quimicos. MX2007002679A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60674204P 2004-09-02 2004-09-02
US61076504P 2004-09-17 2004-09-17
PCT/US2005/031099 WO2006026703A2 (en) 2004-09-02 2005-08-28 Chemical compounds

Publications (1)

Publication Number Publication Date
MX2007002679A true MX2007002679A (es) 2007-05-16

Family

ID=36000724

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2007002679A MX2007002679A (es) 2004-09-02 2005-08-28 Compuestos quimicos.
MX2007002615A MX2007002615A (es) 2004-09-02 2005-08-31 Compuestos quimicos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2007002615A MX2007002615A (es) 2004-09-02 2005-08-31 Compuestos quimicos.

Country Status (16)

Country Link
US (2) US20070254910A1 (es)
EP (2) EP1799671A4 (es)
JP (2) JP2008511669A (es)
KR (2) KR20070053313A (es)
AR (2) AR051565A1 (es)
AU (2) AU2005279835A1 (es)
BR (1) BRPI0514881A (es)
CA (2) CA2579059A1 (es)
IL (1) IL181419A0 (es)
MA (1) MA28872B1 (es)
MX (2) MX2007002679A (es)
NO (2) NO20071366L (es)
PE (2) PE20060656A1 (es)
RU (2) RU2351592C2 (es)
TW (2) TW200612921A (es)
WO (2) WO2006026703A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026703A2 (en) * 2004-09-02 2006-03-09 Smithkline Beecham Corporation Chemical compounds
EP1984376A4 (en) * 2006-01-25 2009-04-08 Smithkline Beecham Corp CHEMICAL COMPOUNDS
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US7767826B2 (en) * 2007-10-05 2010-08-03 Pharmatech International, Inc. Process for the synthesis of L-(+)-ergothioneine
CA2704645A1 (en) * 2007-11-09 2009-05-14 The Salk Institute For Biological Studies Non-nucleoside reverse transcriptase inhibitors
CN102675305B (zh) * 2011-03-08 2014-11-12 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
CN103570683B (zh) * 2012-07-30 2018-04-17 中国科学院上海药物研究所 多取代胺类化合物及其制备方法和用途
HUE045725T2 (hu) 2014-02-13 2020-01-28 Incyte Corp Ciklopropilaminok mint LSD1 inhibitorok
AU2015217073B2 (en) 2014-02-13 2019-08-22 Incyte Holdings Corporation Cyclopropylamines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI714567B (zh) * 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
EP3389634B1 (en) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Methods for treating cancer
KR20180094036A (ko) * 2015-12-15 2018-08-22 브리스톨-마이어스 스큅 컴퍼니 Cxcr4 수용체 길항제
SI3393468T1 (sl) 2015-12-22 2023-01-31 X4 Pharmaceuticals, Inc. Postopki za zdravljenje bolezni imunske pomanjkljivosti
JP2019510785A (ja) 2016-04-08 2019-04-18 エックス4 ファーマシューティカルズ, インコーポレイテッド 癌を処置する方法
WO2017223243A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
EP3471726A4 (en) 2016-06-21 2019-10-09 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
US10759796B2 (en) 2016-06-21 2020-09-01 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
WO2018156595A1 (en) 2017-02-21 2018-08-30 Emory University Chemokine cxcr4 receptor modulators and uses related thereto
WO2019060860A1 (en) * 2017-09-25 2019-03-28 Suzhou Yunxuan Yiyao Keji Youxian Gongsi HETEROARYL COMPOUNDS AS INHIBITORS OF CXCR4, COMPOSITION AND METHOD OF USE THEREOF
JP7282786B2 (ja) * 2017-09-25 2023-05-29 シージーンテック (スーチョウ, チャイナ) カンパニー リミテッド Cxcr4阻害剤としてのヘテロアリール化合物、それを用いた組成物及び方法
EP3768256A4 (en) 2018-03-19 2021-11-24 Emory University PANTROPIC ENTRY INHIBITORS
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734191B2 (en) * 2000-09-15 2004-05-11 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
WO2002022599A2 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
JP2004512336A (ja) * 2000-09-15 2004-04-22 アノーメッド インコーポレイティド ケモカインレセプター結合複素環式化合物
AU9156901A (en) * 2000-09-15 2002-03-26 Anormed Inc Chemokine receptor binding heterocyclic compounds
MXPA04006136A (es) * 2001-12-21 2004-11-01 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada.
WO2004091518A2 (en) * 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
WO2006026703A2 (en) * 2004-09-02 2006-03-09 Smithkline Beecham Corporation Chemical compounds
EP1793825A4 (en) * 2004-09-24 2009-12-09 Smithkline Beecham Corp CHEMICAL COMPOUNDS
WO2007027999A2 (en) * 2005-08-31 2007-03-08 Smithkline Beecham Corporation Chemical compounds

Also Published As

Publication number Publication date
AR051565A1 (es) 2007-01-24
US20070254910A1 (en) 2007-11-01
US20070232615A1 (en) 2007-10-04
AU2005282753A1 (en) 2006-03-16
EP1784185A2 (en) 2007-05-16
AR050302A1 (es) 2006-10-11
RU2352567C2 (ru) 2009-04-20
TW200612921A (en) 2006-05-01
JP2008511668A (ja) 2008-04-17
MA28872B1 (fr) 2007-09-03
NO20071418L (no) 2007-05-31
KR20070049682A (ko) 2007-05-11
WO2006026703A3 (en) 2006-10-05
CA2579059A1 (en) 2006-03-16
WO2006026703A8 (en) 2006-05-26
PE20060656A1 (es) 2006-08-24
EP1799671A2 (en) 2007-06-27
TW200621754A (en) 2006-07-01
MX2007002615A (es) 2007-04-27
CA2578746A1 (en) 2006-03-09
WO2006028896A2 (en) 2006-03-16
JP2008511669A (ja) 2008-04-17
WO2006028896A3 (en) 2006-04-27
IL181419A0 (en) 2007-07-04
RU2007106779A (ru) 2008-10-10
AU2005279835A1 (en) 2006-03-09
NO20071366L (no) 2007-05-31
WO2006026703A2 (en) 2006-03-09
BRPI0514881A (pt) 2008-06-24
KR20070053313A (ko) 2007-05-23
RU2007106780A (ru) 2008-10-10
EP1784185A4 (en) 2009-06-03
RU2351592C2 (ru) 2009-04-10
PE20060712A1 (es) 2006-08-24
EP1799671A4 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
TW200621754A (en) Chemical compounds
TW200619217A (en) Chemical compounds
TW200612935A (en) Chemical compounds
TW200738711A (en) Chemical compounds
WO2006036816A3 (en) Chemical compounds
WO2007027999A3 (en) Chemical compounds
WO2006076131A3 (en) Chemical compounds
WO2007008539A3 (en) Pyranopyridine compounds
WO2007022371A3 (en) Chemokine receptor binding compounds
MX2008001652A (es) Copolimeros de poliamonio-polisiloxano.
WO2006138259A3 (en) Chemokine receptor binding compounds
ZA200705559B (en) IL-7 variants with reduced immunogenicity
WO2007104062A3 (en) Compositions and methods based on peptide binding profiling
MXPA05011353A (es) Compuestos heterociclicos que se unen al receptor de quimiocina con eficacia mejorada.
WO2006125962A3 (en) T cell receptors which specifically bind to vygfvracl-hla-a24
WO2005117557A3 (en) Expression system
IL189555A0 (en) Compositions of cells enriched for combinations of various stem and progenitor cell populations, methods of use thereof and methods of private banking thereof
TNSN07157A1 (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses
WO2006138350A3 (en) Chemokine receptor binding compounds
WO2005059107A3 (en) Chemokine receptor binding compounds
EP1983003A3 (en) Tyrosine phosphorylation sites and antibodies specific for them
MXPA06012987A (es) Epitopos inductores de muerte de celulas t.
EP1975184A3 (en) Serine or threonine phosphorylation sites
WO2006084179A3 (en) Hiv tat-cd4 hybried molecules and methods of use thereof
EP1988103A3 (en) Tyrosine phosphorylation sites and antibodies specific for them

Legal Events

Date Code Title Description
FA Abandonment or withdrawal